Targeting the TGF-β/SMAD3 pathway in DMD could therefore mitigate fibrotic tissue development and reduce inflammation, potentially preserving muscle function and improving patient outcomes (Flanders, 2004). This evidence concerns the gene SMAD3 and Duchenne muscular dystrophy.